JNK mediates insulin-like growth factor binding protein 2/integrin α5-dependent glioma cell migration

International Journal of Oncology

Volumn 37, Issue 1, 2010, Pages 143-153

  Mendes, Kanchana Natarajan ^a   Wang, George K ^a,b,c   Fuller, Gregory N ^a,b   Zhang, Wei ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Glioma; Insulin like growth factor binding protein 2; Integrin 5; JNK

Indexed keywords

ALPHA5 INTEGRIN; FIBRONECTIN; LAMININ; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; SMALL INTERFERING RNA; SOMATOMEDIN BINDING PROTEIN 2; CD51 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BINDING; PROTEIN KINASE INHIBITOR; STRESS ACTIVATED PROTEIN KINASE;

ARTICLE; CANCER CELL CULTURE; CELL ADHESION; CELL MIGRATION; CELL SURFACE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ASSAY; EXTRACELLULAR MATRIX; GLIOMA CELL; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; MEDIATOR; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING; BRAIN TUMOR; CELL MOTION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC TRANSFECTION; GENETICS; GLIOMA; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE;

BRAIN NEOPLASMS; CELL MOVEMENT; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GLIOMA; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INTEGRIN ALPHAV; JNK MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 77953216547     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo-00000662     Document Type: Article

References (58)

1. Cavanee W, Furnari F, Nagane M, et al: Pathology and Genetics of Tumours of the Central Nervous System. Cavanee W and Kleihues P (eds). IARC Press, Lyon, pp9-54, 2000.
2. Prados MD and Levin V: Biology and treatment of malignant glioma. Semin Oncol 27: 1-10, 2000.
3. Behin A, Hoang-Xuan K, Carpentier AF and Delattre JY: Primary brain tumours in adults. Lancet 361: 323-331, 2003.
4. Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK and DePinho RA: Malignant gioma: genetics and biology of a grave matter. Genes Dev 15: 1311-1333, 2001.
5. Clemmons DR: Insulin-like growth factor binding proteins and their role in controlling IGF actions. Cytokine Growth Factor Rev 8: 45-62, 1997. (Pubitemid 27214688)
6. Firth SM and Baxter RC: Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 23: 824-854, 2002. (Pubitemid 35454590)
7. Akmal SN, Yun K, MacLay J, Higami Y and Ikeda T: Insulin-like growth factor 2 and insulin-like growth factor binding protein 2 expression in hepatoblastoma. Hum Pathol 26: 846-851, 1995.
8. Allander SV, Illei PB, Chen Y, Antonescu CR, Bittner M, Ladanyi M and Meltzer PS: Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation. Am J Pathol 161: 1587-1595, 2002. (Pubitemid 35265519)
9. Hoeflich A, Fettscher O, Lahm H, et al: Overexpression of insulin-like growth factor-binding protein-2 results in increased tumorigenic potential in Y-1 adrenocortical tumor cells. Cancer Res 60: 834-838, 2000. (Pubitemid 30129510)
10. Menouny M, Binoux M and Babajko S: Role of insulin-like growth factor binding protein-2 and its limited proteolysis in neuroblastoma cell proliferation: modulation by transforming growth factor-beta and retinoic acid. Endocrinology 138: 683-690, 1997. (Pubitemid 27110919)
11. Michell NP, Dent S, Langman MJ and Eggo MC: Insulin-like growth factor binding proteins as mediators of IGF-I effects on colon cancer cell proliferation. Growth Factors 14: 269-277, 1997.
12. Moore MG, Wetterau LA, Francis MJ, Peehl DM and Cohen P: Novel stimulatory role for insulin-like growth factor binding protein-2 in prostate cancer cells. Int J Cancer 105: 14-19, 2003.
13. Reeve JG, Morgan J, Schwander J and Bleehen NM: Role for membrane and secreted insulin-like growth factor-binding protein-2 in the regulation of insulin-like growth factor action in lung tumors. Cancer Res 53: 4680-4685, 1993.
14. Zumkeller W, Saaf M and Rahn T: Childs Nerv Syst 9: Insulin-like growth factor (IGF)-I, -II and IGF-binding proteins in the cyst fluid of a patient with astrocytoma. Childs Nerv Syst 9: 100-103, 1993.
15. Wang H, Wang H, Zhang W and Fuller GN: Tissue microarrays: applications in neuropathology research, diagnosis, and education. Brain Pathol 12: 95-107, 2002. (Pubitemid 33131366)
16. Fuller GN, Rhee CH, Hess KR, et al: Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: a revelation by parallel gene expression profiling. Cancer Res 59: 4228-4232, 1999.
17. Wang GK, Hu L, Fuller GN and Zhang W: An interaction between insulin-like growth factor-binding protein 2 (IGFBP2) and integrin alpha5 is essential for IGFBP2-induced cell mobility. J Biol Chem 281: 14085-14091, 2006.
18. Wang H, Shen W, Huang H, et al: Insulin-like growth factor binding protein 2 enhances glioblastoma invasion by activating invasion-enhancing genes. Cancer Res 63: 4315-4321, 2003. (Pubitemid 36950996)
19. Zhang W, Wang H, Song SW and Fuller GN: Insulin-like growth factor binding protein 2: gene expression microarrays and the hypothesis-generation paradigm. Brain Pathol 12: 87-94, 2002. (Pubitemid 33131365)
20. Zhou YH, Hess KR, Liu L, Linskey ME and Yung WK: Modeling prognosis for patients with malignant astrocytic gliomas: quantifying the expression of multiple genetic markers and clinical variables. Neuro Oncol 7: 485-494, 2005. (Pubitemid 41555620)
21. Wang ZH, Ma J, Zeng BJ, Catanese VM, Samuels S, Gama Sosa MA and Kolodny EH: Correlation of glioma cell regression with inhibition of insulin-like growth factor 1 and insulin-like growth factor-binding protein-2 expression. Neuroendocrinology 66: 203-211, 1997. (Pubitemid 27356902)
22. Sallinen SL, Sallinen PK, Haapasalo HK, et al: Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res 60: 6617-6622, 2000.
23. Elmlinger MW, Deininger MH, Schuett BS, Meyermann R, Duffner F, Grote EH and Ranke MB: In vivo expression of insulin-like growth factor-binding protein-2 in human gliomas increases with the tumor grade. Endocrinology 142: 1652-1658, 2001.
24. Green BN, Jones SB, Streck RD, Wood TL, Rotwein P and Pintar JE: Distinct expression patterns of insulin-like growth factor binding proteins 2 and 5 during fetal and postnatal development. Endocrinology 134: 954-962, 1994.
25. Lee WH, Michels KM and Bondy CA: Localization of insulin-like growth factor binding protein-2 messenger RNA during postnatal brain development: correlation with insulin-like growth factors I and II. Neuroscience 53: 251-265, 1993.
26. Dunlap S, Celestino J, Wang H, Jiang R, Holland E, Fuller GN and Zhang W: Insulin-like growth factor binding protein 2 promotes glioma development and progression. Proc Natl Acad Sci USA 104: 11736-11741, 2007.
27. Stupack DG and Cheresh DA: Get a ligand, get a life: integrins, signaling and cell survival. J Cell Sci 115: 3729-3738, 2002.
28. Reddig PJ and Juliano RL: Clinging to life: cell to matrix adhesion and cell survival. Cancer Metastasis Rev 24: 425-439, 2005. (Pubitemid 41569982)
29. Milliano MT and Luxon BA: Initial signaling of the fibronectin receptor (alpha5beta1 integrin) in hepatic stellate cells is independent of tyrosine phosphorylation. J Hepatol 39: 32-37, 2003.
30. Takino T, Nakada M, Miyamori H, et al: JSAP1/JIP3 cooperates with focal adhesion kinase to regulate c-Jun N-terminal kinase and cell migration. J Biol Chem 280: 37772-37781, 2005.
31. Krens SF, Spaink HP and Snaar-Jagalska BE: Functions of the MAPK family in vertebrate-development. FEBS Lett 580: 4984-4990, 2006.
32. Aguirre V, Uchida T, Yenush L, Davis R and White MF: The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem 275: 9047-9054, 2000.
33. Otto IM, Raabe T, Rennefahrt UE, Bork P, Rapp UR and Kerkhoff E: The p150-Spir protein provides a link between c-Jun N-terminal kinase function and actin reorganization. Curr Biol 10: 345-348, 2000. (Pubitemid 30186141)
34. Gdalyahu A, Ghosh I, Levy T, et al: DCX, a new mediator of the JNK pathway. EMBO J 23: 823-832, 2004. (Pubitemid 38418749)
35. Chang L, Jones Y, Ellisman MH, Goldstein LS and Karin M: JNK1 is required for maintenance of neuronal microtubules and controls phosphorylation of microtubule-associated proteins. Dev Cell 4: 521-533, 2003. (Pubitemid 36437559)
36. Shin EY, Kim SY and Kim EG: c-Jun N-terminal kinase is involved in motility of endothelial cell. Exp Mol Med 33: 276-283, 2001. (Pubitemid 34534289)
37. Kawauchi T, Chihama K, Nabeshima Y and Hoshino M: The in vivo roles of STEF/Tiam1, Rac1 and JNK in cortical neuronal migration. EMBO J 22: 4190-4201, 2003.
38. Meadows KN, Bryant P, Vincent PA and Pumiglia KM: Activated Ras induces a proangiogenic phenotype in primary endothelial cells. Oncogene 23: 192-200, 2004. (Pubitemid 38142253)
39. Javelaud D, Laboureau J, Gabison E, Verrecchia F and Mauviel A: Disruption of basal JNK activity differentially affects key fibroblast functions important for wound healing. J Biol Chem 278: 24624-24628, 2003. (Pubitemid 37548616)
40. Cox BD, Natarajan M, Stettner MR and Gladson CL: New concepts regarding focal adhesion kinase promotion of cell migration and proliferation. J Cell Biochem 99: 35-52, 2006.
41. Howe AK, Aplin AE and Juliano RL: Anchorage-dependent ERK signaling-mechanisms and consequences. Curr Opin Genet Dev 12: 30-35, 2002.
42. Lee EJ, Mircean C, Shmulevich I, et al: Insulin-like growth factor binding protein 2 promotes ovarian cancer cell invasion. Mol Cancer 4: 7, 2005.
43. Chakrabarty S and Kondratick L: Insulin-like growth factor binding protein-2 stimulates proliferation and activates multiple cascades of the mitogen-activated protein kinase pathways in NIH-OVCAR3 human epithelial ovarian cancer cells. Cancer Biol Ther 5: 189-197, 2006.
44. Turner CE: Paxillin interactions. J Cell Sci 113: 4139-4140, 2000.
45. Kita D, Takino T, Nakada M, Takahashi T, Yamashita J and Sato H: Expression of dominant-negative form of Ets-1 suppresses fibronectin-stimulated cell adhesion and migration through down-regulation of integrin alpha5 expression in U251 glioma cell line. Cancer Res 61: 7985-7991, 2001.
46. Colin C, Baeza N, Bartoli C, et al: Identification of genes differentially expressed in glioblastoma versus pilocytic astrocytoma using Suppression Subtractive Hybridization. Oncogene 25: 2818-2826, 2006.
47. Geiger B, Bershadsky A, Pankov R and Yamada KM: Transmembrane crosstalk between the extracellular matrix-cytoskeleton crosstalk. Nat Rev Mol Cell Biol 2: 793-805, 2001.
48. Larsen M, Tremblay ML and Yamada KM: Phosphatases in cell-matrix adhesion and migration. Nat Rev Mol Cell Biol 4: 700-711, 2003.
49. Li L, Okura M and Imamoto A: Focal adhesions require catalytic activity of Src family kinases to mediate integrin-matrix adhesion. Mol Cell Biol 22: 1203-1217, 2002.
50. Nakamoto T, Sakai R, Honda H, et al: Requirements for localization of p130cas to focal adhesions. Mol Cell Biol 17: 3884-3897, 1997.
51. Hu B, Jarzynka MJ, Guo P, Imanishi Y, Schlaepfer DD and Cheng SY: Angiopoietin 2 induces glioma cell invasion by stimulating matrix metalloprotease 2 expression through the alphavbeta1 integrin and focal adhesion kinase signaling pathway. Cancer Res 66: 775-783, 2006.
52. Dedhar S, Williams B and Hannigan G: Integrin-linked kinase (ILK): a regulator of integrin and growth-factor signalling. Trends Cell Biol 9: 319-323, 1999.
53. Zhang Y, Ikegami T and Honda A: Involvement of integrin-linked kinase in carbon tetrachloride-induced hepatic fibrosis in rats. Hepatology 44: 612-622, 2006. (Pubitemid 44433717)
54. Koul D, Shen R, Bergh S, et al: Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma. Mol Cancer Ther 4: 1681-1688, 2005. (Pubitemid 41685302)
55. Shi C, Zhang X, Chen Z, Robinson MK and Simon DI: Leukocyte integrin Mac-1 recruits toll/interleukin-1 receptor superfamily signaling intermediates to modulate NF-kappaB activity. Circ Res 89: 859-865, 2001. (Pubitemid 34627890)
56. Huangfu WC, Omori E, Akira S, Matsumoto K and Ninomiya-Tsuji J: Osmotic stress activates the TAK1-JNK pathway while blocking TAK1-mediated NF-kappaB activation: TAO2 regulates TAK1 pathways. J Biol Chem 281: 28802-28810, 2006. (Pubitemid 44507023)
57. Wan YY, Chi H, Xie M, Schneider MD and Flavell RA: The kinase TAK1 integrates antigen and cytokine receptor signaling for T cell development, survival and function. Nat Immunol 7: 851-858, 2006. (Pubitemid 44084092)
58. Delaney JR, Stoven S, Uvell H, Anderson KV, Engstrom Y and Mlodzik M: Cooperative control of Drosophila immune responses by the JNK and NF-kappaB signaling pathways. EMBO J 25: 3068-3077, 2006. (Pubitemid 44106759)